Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors

NCT01518413 is registered in ClinicalTrials.gov with HMeany as lead sponsor.

NCT NCT01518413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01518413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Lead sponsor
HMeany
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2011
Completion date
January 31, 2015
Enrollment
17 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumors, ewing's sarcoma family of tumors, neuroblastoma, osteosarcoma, rhabdomyosarcoma and other soft tissue sarcomas